Streetbeat News

Stock Prices

SGU

Star Group (NYSE:SGU) reported a narrower Q4 loss of $(0.55) per share compared to $(1.36) per share in the same quarter last year. However, sales decreased by 10.01% to $266.94M from $296.64M in the same period.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 9:37 pm

GEF

Greif (NYSE:GEF) reported Q4 earnings with an EPS of $1.56, beating estimates by 20.93% but with a revenue decline of $188M from the previous year. Despite beating EPS estimates last quarter, the share price dropped by 1.53% the following day.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 9:35 pm

OXM

Oxford Industries (NYSE:OXM) reported Q3 earnings with an EPS of $1.01, beating estimates by 5.21% and showing a revenue increase of $13.60 million from the same period last year. The company has a history of surpassing EPS estimates, which has previously led to a share price increase the following day.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 9:35 pm

CHWY

Chewy's stock is trading lower following the release of their mixed Q3 financial results and a reduction in their full-year 2023 net sales forecast.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 9:34 pm

OPTT

PGNT

Paragon Technologies (OTC:PGNT), owning 4.9% of Ocean Power Technologies (NYSE:OPTT), criticizes OPTT's board for entrenchment and dishonesty. Paragon's request for a preliminary injunction against OPTT's advance notice bylaws was denied, but the court expressed doubts about the board's good faith. Paragon accuses OPTT of fabricating schemes to block alternate director nominations and questions the board's spending of over $6 million to defend against Paragon's campaign, given OPTT's financial losses and risk of insolvency. Paragon urges shareholders to vote for its director nominees, citing its own track record of creating shareholder value.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 9:33 pm

ABBV

CERE

AbbVie is set to acquire Cerevel Therapeutics for an equity value of about $8.7 billion, causing Cerevel's shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 9:32 pm

ABBV

CERE

AbbVie has announced its intention to acquire Cerevel Therapeutics at a price of $45.00 per share in cash. The total equity value of the transaction is approximately $8.7 billion.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 9:31 pm

BNED

CHWY

JOAN

QRTEA

SPWH

VMAR

After Wednesday's after-market session, several consumer discretionary stocks experienced significant movements. Barnes & Noble Education (BNED) saw a 26.6% increase following their Q2 earnings release. Vision Marine (VMAR) rose by 9.65% after their Q4 earnings report 4 days ago. JOANN (JOAN) increased by 7.58% post Q3 earnings 2 days ago. Selina Hospitality (SLNA), Xcel Brands (XELB), and Tuniu (TOUR) also saw gains. Conversely, SRM Entertainment (SRM), Sportsman's Warehouse (SPWH), Chewy (CHWY), XWELL (XWEL), Yoshiharu Global (YOSH), and Qurate Retail (QRTEA) experienced declines, with SPWH and CHWY dropping post Q3 earnings reports.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 9:31 pm

APDN

BNOX

CERE

CYTO

ERNA

MNPR

MXCT

OPTN

RANI

RSLS

SERA

WVE

In Wednesday's after-market session, several healthcare stocks experienced significant movements. Reshape Lifesciences, Monopar Therapeutics, Cerevel Therapeutics, Altamira Therapeutics, Sera Prognostics, and Bionomics saw their shares rise, with increases ranging from 7.25% to 17.9%. Conversely, WAVE Life Sciences, MaxCyte, Rani Therapeutics, Eterna Therapeutics, Applied DNA Sciences, and OptiNose experienced declines between 5.7% and 18.4%.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 9:31 pm

ACVA

AGX

BGLC

ESGL

GETR

HTOO

NCNC

NKLA

NXU

RMCO

SOS

VSTS

In Wednesday's after-market session, several industrial stocks saw significant movements. Gainers included Nxu, ACV Auctions, SOS, ESGL Holdings, Vestis, and Fusion Fuel Green, with increases ranging from 4.54% to 12.2%. Losers were Getaround, noco-noco, Nikola, Royalty Management Holdings, Argan, and BioNexus Gene Lab, with declines between 3.63% and 5.7%. Notably, Fusion Fuel Green's Q3 earnings were released two days ago, and Argan's Q3 earnings were reported today.

Portfolio Pulse from Benzinga Insights

December 06, 2023 | 9:31 pm